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The Protein Kinase C bII (PKCbII) belongs to conven-
tional class of Protein kinase C enzyme and is preferen-
tially activated during diabetic cardiomyopathy [1]. An
effective inhibition of PKCbII is the potential option to
directly treat the diabetic cardiomyopathy. Till date only
one selective PKCbII inhibitor, ruboxistaurin reached
phase III clinical trial for diabetic complications. Thus,
there is an urgent need for exploring available chemical
space for new PKCbII inhibitors. The sequential virtual
screening workflow based on ligand and receptor based
query was followed to identify novel PKCbII inhibitors.
Three different strategies were followed for developing the
ligand based model by HipHop module implemented in
Catalyst, using: (I) three active and six moderately active
compounds; (II) 17 active compounds; (III) docked poses
of the compounds used in strategy (II). Receptor based
query was developed based on the cocrystallised crystal
structure of PKCbII with 2-methylbisindolylmaleimide
(2mBIM) using the Unity module of Sybyl7.1. The best
hypotheses from both methods consist of six features viz.
one hydrogen bond donor (D), two hydrogen bond accep-
tor (A), two hydrophobic-aromatic (HYD) and one ring
aromatic (R). Virtual screening scheme based on these 3D
hypotheses identified a few molecules with higher docking
score than the existing inhibitors. In addition, comparative
molecular dynamics (MD) simulation studies of uncom-
plexed PKCbII and its complexes with 2mBIM, ruboxis-
taurin and newly identified compounds were performed to
analyze the binding mode of the molecules. This study
showed that complexed form of PKCbII was more stable
than uncomplexed one during simulation period, and
showed the stable H-bond formation with Glu421, Val423.
This reveals the favorable interactions of identified com-
pounds with PKCbII.
Published: 1 May 2012
Reference
1. Murray NR, Baumgardner GP, Burns DJ, Fields AP: Protein kinase C isotypes
in human erythroleukemia (K562) cell proliferation and differentiation.
Evidence that beta II protein kinase C is required for proliferation. J Biol
Chem 1993, 21:15847-15853.
doi:10.1186/1758-2946-4-S1-P45
Cite this article as: Grewal and Sobhia: In silico identification of novel
PKC bII inhibitors: ligand and receptor based pharmacophore modeling,
virtual screening, and molecular dynamics study. Journal of
Cheminformatics 2012 4(Suppl 1):P45.
Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/ Department of Pharmacoinformatics, National Institute of Pharmaceutical
Education and Research (NIPER), Sector 67, S.A.S Nagar, Punjab 160062, India
Grewal and Sobhia Journal of Cheminformatics 2012, 4(Suppl 1):P45
http://www.jcheminf.com/content/4/S1/P45
© 2012 Grewal and Sobhia; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.